Oncogene-Targeting T Cells Reject Large Tumors while Oncogene Inactivation Selects Escape Variants in Mouse Models of Cancer

Cancer Cell

Volumn 20, Issue 6, 2011, Pages 755-767

  Anders, Kathleen ^a   Buschow, Christian ^b   Herrmann, Andreas ^c   Milojkovic, Ana ^b   Loddenkemper, Christoph ^b   Kammertoens, Thomas ^b   Daniel, Peter ^b   Yu, Hua ^c   Charo, Jehad ^a   Blankenstein, Thomas ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BYSTANDER EFFECT; CANCER CELL DESTRUCTION; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; EFFECTOR CELL; FUSION GENE; GENE INACTIVATION; GENE TARGETING; GENETIC STABILITY; GENETIC VARIABILITY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 83455173559     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.10.019     Document Type: Article

References (46)

1. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr. Opin. Immunol. 2005, 17:180-186.
2. Blohm U., Potthoff D., van der Kogel A.J., Pircher H. Solid tumors " melt" from the inside after successful CD8 T cell attack. Eur. J. Immunol. 2006, 36:468-477.
3. Briesemeister D., Sommermeyer D., Loddenkemper C., Loew R., Uckert W., Blankenstein T., Kammertoens T. Tumor rejection by local interferon γ induction in established tumors is associated with blood vessel destruction and necrosis. Int. J. Cancer 2011, 128:371-378.
4. Buschow C., Charo J., Anders K., Loddenkemper C., Jukica A., Alsamah W., Perez C., Willimsky G., Blankenstein T. In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance. J. Immunol. 2010, 184:2930-2938.
5. Casares N., Pequignot M.O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., Schmitt E., Hamai A., Hervas-Stubbs S., Obeid M., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 2005, 202:1691-1701.
6. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
7. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 1999, 4:199-207.
8. Feng H., Shuda M., Chang Y., Moore P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008, 319:1096-1100.
9. Gooding L.R. Characterization of a progressive tumor from C3H fibroblasts transformed in vitro with SV40 virus: immunoresistance in vivo correlates with phenotypic loss of H-2Kk. J. Immunol. 1982, 129:1306-1312.
10. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
11. Gossen M., Bujard H. Studying gene function in eukaryotes by conditional gene inactivation. Annu. Rev. Genet. 2002, 36:153-173.
12. Herrmann A., Kortylewski M., Kujawski M., Zhang C., Reckamp K., Armstrong B., Wang L., Kowolik C., Deng J., Figlin R., Yu H. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010, 70:7455-7464.
13. Hillen W., Berens C. Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu. Rev. Microbiol. 1994, 48:345-369.
14. Hinrichs W., Kisker C., Düvel M., Müller A., Tovar K., Hillen W., Saenger W. Structure of the Tet repressor-tetracycline complex and regulation of antibiotic resistance. Science 1994, 264:418-420.
15. Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 2000, 24:57-60.
16. Jonkers J., Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell 2004, 6:535-538.
17. Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., Kominami E., Ohsumi Y., Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000, 19:5720-5728.
18. Kast W.M., Offringa R., Peters P.J., Voordouw A.C., Meloen R.H., van der Eb A.J., Melief C.J. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 1989, 59:603-614.
19. Knight Z.A., Lin H., Shokat K.M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 2010, 10:130-137.
20. Kondo Y., Kanzawa T., Sawaya R., Kondo S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 2005, 5:726-734.
21. Kuerbitz S.J., Plunkett B.S., Walsh W.V., Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 1992, 89:7491-7495.
22. Kumar V., Fausto N., Abbas A. Neoplasia 2004, W.B. Saunders/Elsevier, Philadelphia. Seventh Edition.
23. Li L.-P., Lampert J.C., Chen X., Leitao C., Popović J., Müller W., Blankenstein T. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat. Med. 2010, 16:1029-1034.
24. Liu J.Q., Bai X.F. Overcoming immune evasion in T cell therapy of cancer: lessons from animal models. Curr. Mol. Med. 2008, 8:68-75.
25. Moody S.E., Sarkisian C.J., Hahn K.T., Gunther E.J., Pickup S., Dugan K.D., Innocent N., Cardiff R.D., Schnall M.D., Chodosh L.A. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002, 2:451-461.
26. Mylin L.M., Schell T.D., Epler M., Kusuma C., Assis D., Matsko C., Smith A., Allebach A., Tevethia S.S. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology 2007, 364:155-168.
27. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
28. Qin Z., Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells. Immunity 2000, 12:677-686.
29. Qin Z., Schwartzkopff J., Pradera F., Kammertoens T., Seliger B., Pircher H., Blankenstein T. A critical requirement of interferon γ-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 2003, 63:4095-4100.
30. Rakhra K., Bachireddy P., Zabuawala T., Zeiser R., Xu L., Kopelman A., Fan A.C., Yang Q., Braunstein L., Crosby E., et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18:485-498.
31. Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J., Yannelli J.R., Rosenberg S.A. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 1996, 88:100-108.
32. Schreiber K., Rowley D.A., Riethmüller G., Schreiber H. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol. Oncol. Clin. North Am. 2006, 20:567-584.
33. Schüler T., Blankenstein T. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J. Immunol. 2003, 170:4427-4431.
34. Schumacher T.N. T-cell-receptor gene therapy. Nat. Rev. Immunol. 2002, 2:512-519.
35. Skipper H.E. The effects of chemotherapy on the kinetics of leukemic cell behavior. Cancer Res. 1965, 25:1544-1550.
36. Spiotto M.T., Rowley D.A., Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 2004, 10:294-298.
37. Staveley-O'Carroll K., Schell T.D., Jimenez M., Mylin L.M., Tevethia M.J., Schoenberger S.P., Tevethia S.S. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J. Immunol. 2003, 171:697-707.
38. Stoler D.L., Chen N., Basik M., Kahlenberg M.S., Rodriguez-Bigas M.A., Petrelli N.J., Anderson G.R. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Natl. Acad. Sci. USA 1999, 96:15121-15126.
39. Tang Y., Kim M., Carrasco D., Kung A.L., Chin L., Weissleder R. In vivo assessment of RAS-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging. Cancer Res. 2005, 65:8324-8330.
40. Uckert W., Kammertöns T., Haack K., Qin Z., Gebert J., Schendel D.J., Blankenstein T. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum. Gene Ther. 1998, 9:855-865.
41. Weinstein I.B. Cancer: addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
42. Willimsky G., Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005, 437:141-146.
43. Willimsky G., Czéh M., Loddenkemper C., Gellermann J., Schmidt K., Wust P., Stein H., Blankenstein T. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 2008, 205:1687-1700.
44. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. 2000, 192:1637-1644.
45. Ying L., Lau A., Alvira C.M., West R., Cann G.M., Zhou B., Kinnear C., Jan E., Sarnow P., Van de Rijn M., Rabinovitch M. LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor. J. Cell Sci. 2009, 122:1441-1451.
46. Zhang B., Karrison T., Rowley D.A., Schreiber H. IFN-γ- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 2008, 118:1398-1404.